Concepedia

Author

Gordon W. Rewcastle

University of AucklandORCID

Also Known As

G W Rewcastle, G. W. REWCASTLE, G. W. Rewcastle, G.W Rewcastle, G.W. Rewcastle, GORDON W REWCASTLE, Gordon Rewcastle, Gordon W Rewcastle, Gordon W. Rewcastle, Gordon William Rewcastle

167

Publications

5.8K

Citations

41

H-Index

80

Concepts

All Affiliations

University of AucklandCancer Society of New ZealandMaurice Wilkins Centre
GW

About

Gordon W. Rewcastle is an author at University of Auckland specializing in pharmacology, medicine, and biochemistry.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

21

35

1.9K

2

Biochemistry

18

26

1.4K

3

Natural Sciences

17

26

1.4K

4

Engineering

13

16

409

5

Health Sciences

4

4

169

Gordon W. Rewcastle

×

88

Publications

5.6K

Citations

40

H-Index

YearCitations

Tyrosine Kinase Inhibitors. 8. An Unusually Steep Structure−Activity Relationship for Analogues of 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a Potent Inhibitor of the Epidermal Growth Factor Receptor

Alexander J. Bridges, Hairong Zhou, Donna R. Cody,

Journal of Medicinal Chemistry

1996

321

Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of minimal DNA-intercalating agents which may not act via topoisomerase II

William A. Denny, Gordon W. Rewcastle, Bruce C. Baguley

Journal of Medicinal Chemistry

1990

309

Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor:  4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-<i>d</i>]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions

Jeff B. Smaill, Gordon W. Rewcastle, Joseph A. Loo,

Journal of Medicinal Chemistry

2000

263

Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor.

Gordon W. Rewcastle, William A. Denny, Alexander J. Bridges,

Journal of Medicinal Chemistry

1995

259

Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling

Claire Chaussade, Gordon W. Rewcastle, Jackie D. Kendall,

Biochemical Journal

2007

225

Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids

Gordon W. Rewcastle, Graham J. Atwell, Li Zhuang,

Journal of Medicinal Chemistry

1991

194

Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide

Graham J. Atwell, Gordon W. Rewcastle, Bruce C. Baguley,

Journal of Medicinal Chemistry

1987

188

Tyrosine Kinase Inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(Phenylamino)pyrido[<i>d</i>]pyrimidine Acrylamides as Irreversible Inhibitors of the ATP Binding Site of the Epidermal Growth Factor Receptor

Jeff B. Smaill, Brian D. Palmer, Gordon W. Rewcastle,

Journal of Medicinal Chemistry

1999

178

A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types

Stephen M. F. Jamieson, Jack U. Flanagan, Sharada Kolekar,

Biochemical Journal

2011

170

Tyrosine Kinase Inhibitors. 9. Synthesis and Evaluation of Fused Tricyclic Quinazoline Analogues as ATP Site Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor

Gordon W. Rewcastle, Brian D. Palmer, Alexander J. Bridges,

Journal of Medicinal Chemistry

1996

149

Page 1